JP2019523633A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523633A5
JP2019523633A5 JP2018556357A JP2018556357A JP2019523633A5 JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5 JP 2018556357 A JP2018556357 A JP 2018556357A JP 2018556357 A JP2018556357 A JP 2018556357A JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5
Authority
JP
Japan
Prior art keywords
cancer
disease
syndrome
inflammation
isolated peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030100 external-priority patent/WO2017189988A1/en
Publication of JP2019523633A publication Critical patent/JP2019523633A/ja
Publication of JP2019523633A5 publication Critical patent/JP2019523633A5/ja
Pending legal-status Critical Current

Links

JP2018556357A 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド Pending JP2019523633A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329743P 2016-04-29 2016-04-29
US62/329,743 2016-04-29
PCT/US2017/030100 WO2017189988A1 (en) 2016-04-29 2017-04-28 Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Publications (2)

Publication Number Publication Date
JP2019523633A JP2019523633A (ja) 2019-08-29
JP2019523633A5 true JP2019523633A5 (enExample) 2020-06-18

Family

ID=60161215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556357A Pending JP2019523633A (ja) 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Country Status (5)

Country Link
US (1) US10864253B2 (enExample)
EP (1) EP3448415A4 (enExample)
JP (1) JP2019523633A (enExample)
CN (1) CN109310741A (enExample)
WO (1) WO2017189988A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144224B (zh) * 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
JP2022529353A (ja) * 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
WO2021119354A1 (en) * 2019-12-13 2021-06-17 Massachusetts Institute Of Technology Synthetic tissue barriers and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
KR20050083682A (ko) 2002-09-09 2005-08-26 워렌 파마슈티칼즈 인코포레이티드 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는 장기 작용성 에리트로포이에틴
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
KR20070008519A (ko) 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CA2595520A1 (en) * 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
US20080305120A1 (en) * 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
MX339613B (es) 2005-08-05 2016-06-02 Araim Pharmaceuticals Inc Peptidos protectores de tejido y sus usos.
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
NZ601868A (en) 2008-01-22 2014-05-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN114106139B (zh) 2011-04-26 2024-08-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
CA2918223A1 (en) * 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
CU20140026A7 (es) 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Similar Documents

Publication Publication Date Title
AU2022200946B2 (en) Modulators of the integrated stress pathway
JP2016531105A5 (enExample)
AU2020281003B2 (en) Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
US10300051B2 (en) Cyclopropylamines as LSD1 inhibitors
ES2718409T3 (es) Síntesis de compuestos de carbomoilpiridona policíclica
ES2690082T3 (es) Derivados de purina para el tratamiento de infecciones virales
CN107922387B (zh) Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
ES2709975T3 (es) Compuestos inmunomoduladores y antiinflamatorios novedosos
ES2499028T3 (es) Derivados de anilino-pirimidina sustituidos con sulfoximina como inhibidores de CDK, su preparación y uso como medicamentos
ES2805835T3 (es) Compuestos policíclicos como inhibidores de quinasa de tirosina de Bruton
KR20180124149A (ko) 단백질 조정제로서 유용한 헤테로시클릭 아미드
JP2019523633A5 (enExample)
CN110898067A (zh) 癌症治疗方法
RU2014121073A (ru) Бициклические соединения пиперазина
AU2013326429B2 (en) N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists
SA515360611B1 (ar) مشتقات كلورو-بيرازين كربوكساميد مفيدة لعلاج أمراض مصحوبة بترطيب مخاطي غير كافي
CN107735401B (zh) 取代二氢吡咯并吡唑衍生物
ES2567709T3 (es) Derivados de anilinopirimidina sustituidos con sulfona como inhibidores de CDK, su preparación y su uso como fármaco
US10987349B2 (en) Antitumor agent and bromodomain inhibitor
Meng et al. Synthesis and biological evaluation of 6H-pyrido [2′, 1′: 2, 3] imidazo [4, 5-c] isoquinolin-5 (6H)-ones as antimitotic agents and inhibitors of tubulin polymerization
WO2009067856A1 (fr) Inhibiteur de l'histone désacétylase, composition et utilisation de celui-ci
WO2019100061A1 (en) Oxoacridinyl acetic acid derivatives and methods of use
JP6262363B2 (ja) ブロモドメイン阻害剤としてのキノリン誘導体
ES2963447T3 (es) Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble